Over 200 companies are advancing next-generation obesity therapies, with more than 30 drugs in late-stage development and 180+ in mid and early stages. Key players include Eli Lilly, Novo Nordisk, Viking Therapeutics, and Roche, developing innovative mechanisms like dual GLP-1/GIP receptor agonists and triple hormone receptor agonists. Recent approvals include Novo Nordisk's oral Wegovy formulation and Eli Lilly's orforglipron, while multiple Phase III trials show promising weight loss results.

Viking Therapeutics announced the initiation of the SUNRISE phase III program to evaluate its oral VK2735 formulation for obesity treatment. The program consists of two studies targeting 560 adults each, with and without type 2 diabetes. Phase II results showed up to 12.2% mean weight loss at the highest dose versus 1.3% with placebo. Despite positive developments, VKTX stock declined 4.4% on the announcement day and is down 27.6% year-to-date.

The article highlights four high-risk, high-reward stocks: Agios Pharmaceuticals awaiting FDA approval for mitapivat to treat sickle cell disease; Navitas Semiconductor pivoting toward AI data centers and high-power chips; Joby Aviation developing eVTOL transportation services with autonomous capabilities; and Viking Therapeutics developing obesity drug VK2735 with potential in a multi-billion dollar market. All require patience but offer significant upside if their respective catalysts materialize.

Novo Nordisk shares fell 11.1% over the past month following disappointing Capital Markets Day guidance that lacked near-term clarity. The company faces headwinds from intensifying competition with Eli Lilly's obesity drugs, lower U.S. pricing pressure, and pipeline setbacks including the failed CagriSema trial. While long-term opportunities exist in rare diseases and next-generation GLP-1 candidates, short-term investors should wait for stabilization signs, though long-term holders may maintain positions given valuation discounts and market potential.

Oppenheimer analyst Jay Olson raised his price target on Viking Therapeutics to $120 from $100, implying a potential quadrupling from the current $28.50 price. The bullish call is based on positive maintenance trial data for VK2735, a GLP-1 and GIP agonist drug, which increased the probability of success from 80% to 90%. Wall Street consensus projects VK2735 could generate $1.5 billion in 2030 sales rising to $6.5 billion by 2035, potentially capturing market share from Eli Lilly's tirzepatide, which is expected to reach $80 billion in total sales by 2030.

Viking Therapeutics is advancing its oral weight-loss drug VK2735 to Phase 3 trials, showing 12.2% weight loss in Phase 2 testing. However, the company faces significant competitive challenges from established players like Eli Lilly's Foundayo, which demonstrated better tolerability with lower discontinuation rates. While Viking's injectable formulation shows promise with potential monthly dosing differentiation, the biotech will struggle to gain market traction in an increasingly crowded obesity drug market dominated by incumbents.

Viking Therapeutics (VKTX) closed at $28.53, up 2.88% and outperforming the S&P 500's 0.6% gain. However, the stock has declined 13.69% over the past month. The company is expected to report an EPS of -$1 (down 23.46% YoY) with annual earnings projected at -$4.46 per share and zero revenue. Despite negative earnings outlook, VKTX holds a Zacks Rank #2 (Buy) rating with a slight 0.16% upward revision in consensus EPS projections over the past 30 days.

Viking Therapeutics (VKTX) declined 2.84% to $27.73, underperforming the S&P 500's 0.47% loss. The stock has fallen 12.72% over the past month, significantly trailing the Medical sector's 3.97% decline. The company is projected to report negative earnings of -$1 per share with a 23.46% year-over-year decline, and annual estimates show -$4.47 EPS with zero revenue. Despite these challenges, VKTX maintains a Zacks Rank #2 (Buy) rating with no recent changes to consensus estimates.

Eli Lilly's stock has declined 2.3% in three months despite strong business fundamentals, driven by valuation concerns and competition worries rather than operational deterioration. The company's GLP-1 drugs Mounjaro and Zepbound generated $27.7 billion in first-half 2026 sales, while newly launched oral pill Foundayo is gaining traction with coverage from all major PBMs. Lilly is successfully diversifying beyond GLP-1 with non-cardiometabolic revenues growing 121% in Q2, and the pipeline includes promising candidates like retatrutide. However, headwinds include pricing pressure, rising competition, and slower expected second-half growth.

Viking Therapeutics initiated a clinical study testing oral and injectable maintenance dosing regimens for VK2735, its lead obesity candidate. Earlier results showed every-other-week and monthly dosing retained approximately 90% and 85% of prior weight loss respectively. The company plans to start late-stage oral studies by year-end, though it faces intense competition from Eli Lilly and Novo Nordisk's established obesity treatments.

Eli Lilly, the only healthcare stock in the trillion-dollar club, has rallied 400% over five years driven by its successful GLP-1 drugs Mounjaro and Zepbound. However, with a valuation of 40x trailing earnings and slowing growth prospects, the stock faces significant headwinds from intensifying competition in the GLP-1 market from companies like Pfizer and Viking Therapeutics. The author suggests the stock may have more downside risk than upside potential at current valuations.

The article recommends four stocks for October investment: Viking Therapeutics for its unique monthly-dose GLP-1 weight loss drug candidate in a market expected to reach $200 billion by 2030; Alphabet for its dominant position in cloud computing AI services with 82% YoY growth and gaining market share; SoFi Technologies for strong revenue growth (40% YoY) and customer expansion despite recent setbacks; and MercadoLibre for its Amazon-like growth trajectory in Latin America with 50% YoY revenue growth despite margin pressures from free shipping initiatives.